Effectiveness and safety of interferon α-2a combined with phototherapy for patients with early-stage mycosis fungoides - a single-arm prospective study in 13 patients

References

• Larocca CA, Leboeuf NR. Overview of cutaneous T-cell lymphomas [J]. Hematol Oncol Clin North Am. 2019;33(4):1–9. doi: 10.1016/j.hoc.2019.04.004.
   PubMed Web of Science ®Google Scholar
• Pattamadilok B, Poomputsar T. A retrospective, descriptive study of patients with mycosis fungoides treated by phototherapy (oral PUVA, NB-UVB) with a twice-weekly regimen at the institute of dermatology, Bangkok, Thailand, with an experiential timeline of 13 years [J]. Photodermatol Photoimmunol Photomed. 2021;37(1):49–55. doi: 10.1111/phpp.12611.
   PubMed Web of Science ®Google Scholar
• Dogra S, Mahajan R. Phototherapy for mycosis fungoides [J]. Indian J Dermatol Venereol Leprol. 2015;81(2):124–135. doi: 10.4103/0378-6323.152169.
   PubMed Web of Science ®Google Scholar
• Sigmundsdottir H, Johnston A, Gudjonsson JE, et al. Narrowband-UVB irradiation decreases the production of pro-inflammatory cytokines by stimulated T cells [J]. Arch Dermatol Res. 2005;297(1):39–42. doi: 10.1007/s00403-005-0565-9.
   PubMed Web of Science ®Google Scholar
• Weiner DM, Durgin JS, Wysocka M, et al. The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: current and future approaches [J]. J Am Acad Dermatol. 2021;84(3):597–604. doi: 10.1016/j.jaad.2020.12.026.
   PubMed Web of Science ®Google Scholar
• Yoo EK, Cassin M, Lessin SR, et al. Complete molecular remission during biologic response modifier therapy for Sézary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity [J]. J Am Acad Dermatol. 2001;45(2):208–216. doi: 10.1067/mjd.2001.116345.
   PubMed Web of Science ®Google Scholar
• Dinarello CA, Mier JW. Lymphokines [J]. N Engl J Med. 1987;317(15):940–945. doi: 10.1056/NEJM198710083171506.
   PubMed Web of Science ®Google Scholar
• Suchin KR, Cassin M, Gottleib SL, et al. Increased interleukin 5 production in eosinophilic sézary syndrome: regulation by interferon alfa and interleukin 12 [J]. J Am Acad Dermatol. 2001;44(1):28–32. doi: 10.1067/mjd.2001.109853.
   PubMed Web of Science ®Google Scholar
• Rook AH, Heald P. The immunopathogenesis of cutaneous T-cell lymphoma [J]. Hematol/Oncol Clin North Am. 1995;9(5):997–1010. doi: 10.1016/S0889-8588(18)30054-6.
   PubMed Web of Science ®Google Scholar
• Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and sezary syndrome: a proposal of the international society for cutaneous lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC) [J]. Blood. 2007;110(6):1713–1722. doi: 10.1182/blood-2007-03-055749.
   PubMed Web of Science ®Google Scholar
• Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma [J]. J Clin Oncol. 2007;25(21):3109–3115. doi: 10.1200/JCO.2006.10.2434.
   PubMed Web of Science ®Google Scholar
• Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the international society for cutaneous lymphomas, the United States cutaneous lymphoma consortium, and the cutaneous lymphoma task force of the European Organisation for Research and Treatment of Cancer [J]. J Clin Oncol. 2011;29(18):2598–2607. doi: 10.1200/JCO.2010.32.0630.
   PubMed Web of Science ®Google Scholar
• Imam MH, Shenoy PJ, Flowers CR, et al. Incidence and survival patterns of cutaneous T-cell lymphomas in the United States [J]. Leuk Lymphoma. 2013;54(4):752–759. doi: 10.3109/10428194.2012.729831.
   PubMed Web of Science ®Google Scholar
• Cerroni L. Mycosis fungoides-clinical and histopathologic features, differential diagnosis, and treatment [J]. Semin Cutan Med Surg. 2018;37(1):2–10. doi: 10.12788/j.sder.2018.002.
   PubMed Web of Science ®Google Scholar
• Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal [J]. J Clin Oncol. 2010;28(31):4730–4739. doi: 10.1200/JCO.2009.27.7665.
   PubMed Web of Science ®Google Scholar
• Edelson RL. Outsmarting cutaneous T-cell lymphoma cells by decoding the language they speak: focusing past and present insights on future prospects [J]. Clin Lymphoma Myeloma Leuk. 2010;10 Suppl 2:S59–S62. doi: 10.3816/CLML.2010.s.008.
   PubMed Web of Science ®Google Scholar
• Lazear HM, Schoggins JW, Diamond MS. Shared and distinct functions of type I and type III interferons [J]. Immunity. 2019;50(4):907–923. doi: 10.1016/j.immuni.2019.03.025.
   PubMed Web of Science ®Google Scholar
• GöKŞIN Ş, İmren IG, Cenk H, et al. The use of interferon-α2a as monotherapy in stage IB patients with mycosis fungoides: a retrospective chart review of patient outcomes [J]. Dermatol Ther. 2022;35(4):e15344. doi: 10.1111/dth.15344.
   PubMed Web of Science ®Google Scholar
• Olisova OY, Megna M, Grekova EV, et al. PUVA and interferon α2b combined therapy for patients with mycosis fungoides at different stages of the disease: a seven-year retrospective study in Russia [J]. J Eur Acad Dermatol Venereol. 2019;33(2):e72–e4. doi: 10.1111/jdv.15212.
   PubMed Web of Science ®Google Scholar
• Cotler SJ, Wartelle CF, Larson AM, et al. Pretreatment symptoms and dosing regimen predict side-effects of interferon therapy for hepatitis C [J]. J Viral Hepat. 2000;7(3):211–217. doi: 10.1046/j.1365-2893.2000.00215.x.
   PubMed Web of Science ®Google Scholar
• Trask PC, Esper P, Riba M, et al. Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions [J]. J Clin Oncol. 2000;18(11):2316–2326. doi: 10.1200/JCO.2000.18.11.2316.
   PubMed Web of Science ®Google Scholar
• Zhang P, Wu MX. A clinical review of phototherapy for psoriasis [J]. Lasers Med Sci. 2018;33(1):173–180. doi: 10.1007/s10103-017-2360-1.
   PubMed Web of Science ®Google Scholar